Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

by Team Lumida
April 10, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • The U.S. general fertility rate fell to a record low of 53.1 births per 1,000 women ages 15–44 in 2025, according to provisional CDC data — continuing a decline that began in 2007 and has now persisted through six straight years of flat births (~3.6 million annually)
  • The total fertility rate — the average number of children a woman would have over her lifetime at current rates — dropped to 1.57 in 2025, well below the 2.1 replacement level; the U.S. population will eventually shrink without sustained immigration if this trend continues
  • For the first time in U.S. history, birthrates for women in their late 30s exceeded those for women in their early 20s — a structural shift reflecting delayed parenthood driven by financial uncertainty, relationship instability, and political climate concerns
  • The teen birthrate fell 7% in 2025, extending a decades-long decline; since 2007, the birthrate for 15–19-year-olds has fallen 72%, while births over deaths now produce only a half-million net surplus annually — a surplus Census projects will disappear within a decade

What Happened?

New federal data from the CDC shows that America’s fertility rate fell to a record low in 2025 for the sixth consecutive year of flat total births. The general fertility rate — births per 1,000 women ages 15 to 44 — reached 53.1, its lowest point on record. The total fertility rate dropped to 1.57 births per woman, a WSJ calculation shows, significantly below the 2.1 replacement level required for a population to sustain itself without immigration. A historic milestone was crossed in 2025: for the first time, birthrates for women in their late 30s exceeded those of women in their early 20s, reflecting the long-running shift toward delayed parenthood across generations of American women.

Why It Matters?

The fertility decline is not merely a demographic abstraction — it has direct implications for the U.S. economy, retirement systems, and the labor force over the next two to three decades. Flat births and a rising number of deaths are already shrinking the natural population surplus: the U.S. recorded just over 500,000 more births than deaths in 2025. Census Bureau and CBO projections suggest this surplus will disappear within the next decade. After that, population growth — and with it, the labor force, tax base, and economic dynamism that underpin Social Security and Medicare — will depend entirely on immigration. Demographers note that many women still want children but are waiting until financial and relational conditions feel stable enough, suggesting the gap between desired and actual fertility is structural and policy-amenable, not purely cultural.

What’s Next?

The U.S. fertility rate, while at a record low, remains higher than in many other developed nations — the UN estimates more than half of all countries are already below replacement level globally. But the gap is narrowing, and the U.S. no longer has a meaningful demographic edge over peers. Policy levers that other countries have tried — paid family leave, childcare subsidies, child tax credits — have produced mixed results in shifting fertility rates. The more immediate policy question is immigration: the same restrictionist impulses that have driven recent U.S. immigration enforcement could, if sustained, eliminate the demographic safety valve just as natural population growth runs out. How Washington navigates that tension over the next decade may be one of the most consequential long-run policy choices the country faces.

Source: The Wall Street Journal

Previous Post

Anthropic’s New AI Model Is So Dangerous Bessent and Powell Called an Emergency Meeting With Bank CEOs

Next Post

The ‘Busan Freeze’: How Trump Quietly Abandoned His Tough-on-China Playbook

Recommended For You

GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

by Team Lumida
2 days ago
GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

As 13 million Americans take GLP-1 drugs like Ozempic and Mounjaro, a growing body of research warns the drugs can cause up to 10% lean muscle loss —...

Read more

Hospital at Home Linked to Lower Mortality and Fewer ER Visits, JAMA Study Finds

by Team Lumida
1 week ago
dextrose hanging on stainless steel IV stand

A new JAMA Network Open study of Medicare data shows hospital-at-home programs reduce in-hospital mortality, ED visits, and ICU escalations — but adoption is concentrated in urban hospitals...

Read more

8 Evidence-Based Tips for Healthy Eating, According to the NHS

by Team Lumida
1 week ago
vegetable salad

From starchy carbs to salt limits, the UK's National Health Service lays out the practical fundamentals of a balanced diet — and most adults are still getting it...

Read more

The FDA Is Fast-Tracking Psychedelics. The Infrastructure to Support Them Isn’t Ready.

by Team Lumida
2 weeks ago
Abstract colorful psychedelic swirling patterns

Trump's executive order to accelerate psychedelic drug development is welcome — but Bloomberg Opinion's Lisa Jarvis warns the ketamine clinic free-for-all is a cautionary tale the FDA must...

Read more

Ultrasound on a Chip: Butterfly Network’s $4,000 Device Is Taking Medical Imaging Global

by Team Lumida
3 weeks ago
a person holding a tablet

Butterfly Network's semiconductor-based handheld ultrasound costs a fraction of traditional machines and has reached 150,000 deployments worldwide, pairing AI with imaging to put diagnostics in the hands of...

Read more

Nearly 1 in 8 Americans Now Uses Sleep Aids — and Pharma Is Taking Notice

by Team Lumida
3 weeks ago
woman sleeping on bed under blankets

A new federal study finds 13% of U.S. adults rely on prescription drugs, OTC supplements, marijuana, or CBD to sleep, as Eli Lilly's $7.8B acquisition of a sleep...

Read more

Amazon One Medical Launches GLP-1 Weight Loss Program at $25 a Month

by Team Lumida
3 weeks ago
Amazon Targets Rural America: A Game-Changer for Delivery Services

Amazon One Medical is rolling out a weight management program that includes GLP-1 medications, offering compounded pills starting at $25/month with same-day delivery in 3,000 cities.

Read more

Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

by Team Lumida
1 month ago
Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

Melatonin is generally safe for short-term use and non-habit-forming, but it carries real side effects and drug interactions that most users overlook — Mayo Clinic breaks down what...

Read more

How Much Muscle Should You Have — and What Happens When You Lose It?

by Team Lumida
1 month ago
diagram

Muscle mass averages, why they matter for long-term health, and what the science says about measuring and building skeletal muscle across every age group.

Read more

AI Scribes Save Clinicians 13–16 Minutes a Day — and Boost Visit Volume by 1.7%, Study Finds

by Team Lumida
1 month ago
AI Investment Boom: How Tech Giants Are Leading the Charge

The largest study of AI scribe adoption to date — 8,500+ clinicians across five academic medical centers — found the tools cut EHR time by 3% and documentation...

Read more
Next Post
China’s Bold Economic Moves: What You Need to Know Now

The 'Busan Freeze': How Trump Quietly Abandoned His Tough-on-China Playbook

White House, Washington DC

White House Sent Staff-Wide Email Warning Against Insider Trading on Iran War Bets

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

sliced green avocado fruit

Avocados Are the Metabolic Health Hack Most Diets Miss

March 12, 2026
Bitcoin’s Hopes Dashed: China’s Stimulus Shortfall

Bitcoin’s Hopes Dashed: China’s Stimulus Shortfall

October 8, 2024
a computer screen with a bunch of data on it

US Stock Futures Steady Ahead of Key Inflation Data

February 12, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018